These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 19474376)

  • 1. Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?
    Schor-Bardach R; Alsop DC; Pedrosa I; Solazzo SA; Wang X; Marquis RP; Atkins MB; Regan M; Signoretti S; Lenkinski RE; Goldberg SN
    Radiology; 2009 Jun; 251(3):731-42. PubMed ID: 19474376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.
    Wang X; Zhang L; Goldberg SN; Bhasin M; Brown V; Alsop DC; Signoretti S; Mier JW; Atkins MB; Bhatt RS
    J Transl Med; 2011 Dec; 9():220. PubMed ID: 22188900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice.
    Hakimé A; Hines-Peralta A; Peddi H; Atkins MB; Sukhatme VP; Signoretti S; Regan M; Goldberg SN
    Radiology; 2007 Aug; 244(2):464-70. PubMed ID: 17641366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression.
    Zhang L; Bhasin M; Schor-Bardach R; Wang X; Collins MP; Panka D; Putheti P; Signoretti S; Alsop DC; Libermann T; Atkins MB; Mier JW; Goldberg SN; Bhatt RS
    PLoS One; 2011 Apr; 6(4):e19144. PubMed ID: 21559452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model.
    Yuen JS; Sim MY; Siml HG; Chong TW; Lau WK; Cheng CW; Huynh H
    Br J Cancer; 2011 Mar; 104(6):941-7. PubMed ID: 21407223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma.
    Murakami M; Zhao S; Zhao Y; Chowdhury NF; Yu W; Nishijima K; Takiguchi M; Tamaki N; Kuge Y
    Int J Oncol; 2012 Nov; 41(5):1593-600. PubMed ID: 22965141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy.
    Sabir A; Schor-Bardach R; Wilcox CJ; Rahmanuddin S; Atkins MB; Kruskal JB; Signoretti S; Raptopoulos VD; Goldberg SN
    AJR Am J Roentgenol; 2008 Jul; 191(1):133-9. PubMed ID: 18562736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib.
    Kang HC; Tan KS; Keefe SM; Heitjan DF; Siegelman ES; Flaherty KT; O'Dwyer PJ; Rosen MA
    AJR Am J Roentgenol; 2013 Jan; 200(1):120-6. PubMed ID: 23255750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1).
    De Bazelaire C; Rofsky NM; Duhamel G; Michaelson MD; George D; Alsop DC
    Acad Radiol; 2005 Mar; 12(3):347-57. PubMed ID: 15766695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arterial spin-labeling MR imaging of renal masses: correlation with histopathologic findings.
    Lanzman RS; Robson PM; Sun MR; Patel AD; Mentore K; Wagner AA; Genega EM; Rofsky NM; Alsop DC; Pedrosa I
    Radiology; 2012 Dec; 265(3):799-808. PubMed ID: 23047841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
    Hahn OM; Yang C; Medved M; Karczmar G; Kistner E; Karrison T; Manchen E; Mitchell M; Ratain MJ; Stadler WM
    J Clin Oncol; 2008 Oct; 26(28):4572-8. PubMed ID: 18824708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines.
    Tochizawa S; Masumori N; Yanai Y; Ohmoto Y; Yabuuchi Y; Tsukamoto T
    Biomed Res; 2008 Dec; 29(6):271-8. PubMed ID: 19129670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma.
    Flaherty KT; Rosen MA; Heitjan DF; Gallagher ML; Schwartz B; Schnall MD; O'Dwyer PJ
    Cancer Biol Ther; 2008 Apr; 7(4):496-501. PubMed ID: 18219225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal cell cancer presented with leptomeningeal carcinomatosis effectively treated with sorafenib.
    Ranze O; Hofmann E; Distelrath A; Hoeffkes HG
    Onkologie; 2007 Sep; 30(8-9):450-1. PubMed ID: 17848817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
    Chang YS; Adnane J; Trail PA; Levy J; Henderson A; Xue D; Bortolon E; Ichetovkin M; Chen C; McNabola A; Wilkie D; Carter CA; Taylor IC; Lynch M; Wilhelm S
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):561-74. PubMed ID: 17160391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.
    Richards TM; Plowman PN; Reznek R; Ball SA
    Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):633-4. PubMed ID: 19380217
    [No Abstract]   [Full Text] [Related]  

  • 17. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
    Yuen JS; Sim MY; Sim HG; Chong TW; Lau WK; Cheng CW; Ong RW; Huynh H
    Int J Oncol; 2012 Aug; 41(2):712-20. PubMed ID: 22641227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model.
    Kususda Y; Miyake H; Gleave ME; Fujisawa M
    Br J Cancer; 2012 Jun; 106(12):1945-52. PubMed ID: 22588555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.
    de Bazelaire C; Alsop DC; George D; Pedrosa I; Wang Y; Michaelson MD; Rofsky NM
    Clin Cancer Res; 2008 Sep; 14(17):5548-54. PubMed ID: 18765547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.